Search results for "infusion"

showing 3 items of 233 documents

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study

2017

AIM To assess the impact of short infliximab (IFX) infusion on hospital resource utilization and costs. METHODS All inflammatory bowel diseases (IBD) patients who received IFX 1 h infusion from March 2007 to September 2014 in eight centers from Southern Italy were included in the analysis. Demographic, clinical and infusion related data were collected. The potential benefits related to the short infusion protocol were assessed both in terms of time saving and increased infusion unit capacity. In addition, indirect patient-related cost savings were evaluated. RESULTS One hundred and twenty-five patients were recruited (64 with ulcerative colitis and 61 with Crohn’s disease). Median duration …

musculoskeletal diseasesmedicine.medical_specialtyObservational StudyCost savings03 medical and health sciences0302 clinical medicineInternal medicinemedicineIn patient030212 general & internal medicineEconomic impact analysisskin and connective tissue diseasesProtocol (science)business.industryInflammatory Bowel DiseasesOne-hour infusionInfliximabInfliximabMulticenter studyCost savingsstomatognathic diseasesEconomic impactMulticenter studyPhysical therapy030211 gastroenterology & hepatologybusinessmedicine.drugWorld Journal of Gastrointestinal Pharmacology and Therapeutics
researchProduct

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side ef…

2007

Objective: To evaluate the efficacy of switching to etanercept treatment in patients with rheumatoid arthritis who already responded to infliximab, but presented side effects. Methods: Charts of 553 patients with rheumatoid arthritis were retrospectively reviewed to select patients who responded to the treatment with infliximab and switched to etanercept because of occurrence of adverse effects. Clinical data were gathered during 24 weeks of etanercept treatment and for the same period of infliximab treatment before infliximab was stopped. Disease Activity Score computed on 44 joints (DAS-44), erythrocyte sedimentation rate (ESR) 1st hour, Visual Analogue Scale (VAS) of pain, Health Assessm…

rheumatoid arthritisMaleConcise ReportArthritisGastroenterologyReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis Rheumatoidimmune system diseasesImmunology and AllergyHealth Status Indicatorsskin and connective tissue diseasesmedicine.diagnostic_testbiologyAntibodies MonoclonalMiddle AgedC-Reactive ProteinTreatment OutcomeBiologic agents; etanercept; infliximab; infusion reactionRheumatoid arthritisErythrocyte sedimentation rateAntirheumatic AgentsFemalemedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtyVisual analogue scaleImmunologyBlood Sedimentationinfusion reactionGeneral Biochemistry Genetics and Molecular BiologyRheumatologyInternal medicinemedicineHumansAdverse effectRetrospective StudiesChi-Square Distributionbusiness.industryTumor Necrosis Factor-alphaC-reactive proteinetanercept; infliximab; rheumatoid arthritismedicine.diseaseInfliximabInfliximabSurgeryBiologic agentsstomatognathic diseasesImmunoglobulin Gbiology.proteinbusinessinfliximabetanercept
researchProduct

Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitab…

2007

trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer
researchProduct